While its diagnostic utility is clinically validated, emerging evidences reveal that KLK3 mRNA detection in whole blood has a predictive role in tumor progression and therapeutic resistance, which is expected to become a potential prognostic marker for PCa (Boerrigter et al., 2021; Cho et al., 2024). The gene discussed is KLK3; the disease is posterior cortical atrophy.